key: cord-1040365-msdd8btr
authors: Kim, Jin Yong; Jang, Young Rock; Hong, Jang Hee; Jung, Jin Gyu; Park, Jae-Hyeong; Streinu-Cercel, Adrian; Streinu-Cercel, Anca; Săndulescu, Oana; Lee, Sang Joon; Kim, Sung Hyun; Jung, Na Hyun; Lee, Seul Gi; Park, Jeong Eun; Kim, Min Kyung; Jeon, Da Bee; Lee, Yeo Jin; Kim, Bum Soo; Lee, Yeon Mi; Kim, Yeon-Sook
title: Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled Phase 1 Studies in Healthy Subjects and Patients with Mild SARS-CoV-2 Infection
date: 2021-08-23
journal: Clin Ther
DOI: 10.1016/j.clinthera.2021.08.009
sha: 133e6bb886b7e33b6013889d5dd37c448a5173b5
doc_id: 1040365
cord_uid: msdd8btr

PURPOSE: Neutralizing antibodies can reduce severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cellular entry, viral titers, and pathological damage. CT-P59 (regdanvimab), a SARS-CoV-2 neutralizing monoclonal antibody, was examined in 2 randomized, double-blind, placebo-controlled, single ascending dose, phase 1 studies. METHODS: In study 1.1, healthy adults were sequentially enrolled to receive CT-P59 10, 20, 40, or 80 mg/kg, or placebo. In study 1.2, adult patients with mild SARS-CoV-2 infection were enrolled to receive CT-P59 20, 40, or 80 mg/kg, or placebo. Primary objectives of both studies were safety and tolerability up to day 14 post-infusion. Secondary endpoints included pharmacokinetics. Study 1.2 also measured virology and clinical efficacy. FINDINGS: Thirty-two subjects were randomized to study 1.1 (6 per CT-P59 dose cohort; 8 placebo). By day 14 post-infusion, adverse events (AEs) were reported in 2 subjects receiving CT-P59 20 mg/kg (headache, elevated C-reactive protein) and 1 receiving CT-P59 40 mg/kg (pyrexia); all CTCAE grade 1. In study 1.2, 18 patients were randomized (5 per dose cohort; 3 placebo). Sixteen AEs were reported in 10 patients receiving CT-P59. No AEs in either study led to study discontinuation. Greater reductions in viral titers were reported with CT-P59 than placebo in those with maximum titers >10(5) copies/mL. Mean time to recovery was 3.39 versus 5.25 days, respectively. IMPLICATIONS: CT-P59 exhibited a promising safety profile in healthy subjects and patients with mild SARS-CoV-2 infection, with potential antiviral and clinical efficacy in patients with mild SARS-CoV-2 infection. TRIAL REGISTRATION: Study 1.1: EudraCT, 2020-003065-19; NCT04525079. Study 1.2: EudraCT, 2020-003165-19; NCT04593641.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is a global public health crisis. 1,2 While public health containment measures represent the main mitigation strategy to restrict spread of the virus, effective treatments are also urgently required. Accelerated clinical research programs are evaluating a myriad of potential treatment approaches, including antiviral drugs, anti-inflammatory agents, and targeted immunomodulatory therapies, as well as vaccines. 3 Entry of the coronavirus into host cells is an important determinant of viral infectivity and pathogenesis. This process is mediated through binding of the SARS-CoV-2 spike (S) protein to the angiotensin-converting enzyme 2 (ACE2) receptor located on epithelial and endothelial cells. 4 Patients with SARS-CoV-2 infection exhibit a neutralizing antibody response against the S protein, which reduces cellular entry of SARS-CoV-2, decreases viral titers, reduces pathological damage arising from infection, and alleviates the symptoms of infection in rodent and primate models of SARS-CoV-2 infection. [5] [6] [7] [8] There is also evidence that neutralizing S-reactive antibodies may confer immunity to SARS-CoV-2 infection in humans. 9 Collectively, these studies provide proof of principle for the use of antibody therapy against the SARS-CoV-2 S protein in the treatment of SARS-CoV-2 infection.

CT-P59, a potent neutralizing monoclonal antibody against various SARS-CoV-2 isolates, was identified through screening human monoclonal antibodies from the peripheral blood mononuclear cells of a SARS-CoV-2 convalescent patient. 10 Complex crystal structure studies of the CT-P59 antigen-binding fragment/SARS-CoV-2 receptor-binding domain (RBD) suggest that CT-P59 blocks the interaction regions between SARS-CoV-2 S protein RBD and ACE2. CT-P59 has been shown to inhibit SARS-CoV-2 replication in vitro with a half-maximal inhibitory concentration of 8 ng/mL, and animal models of SARS-CoV-2 infection indicate that CT-P59 is associated with a substantial reduction in viral load and alleviation of clinical symptoms. 10 Herein, we report the outcomes from the first-in-human clinical evaluations of the SARS-CoV-2 antibody, CT-P59. We conducted 2 phase 1, single ascending dose studies, primarily to assess the safety and pharmacokinetics of CT-P59 in healthy volunteers, and safety, virologic efficacy, and pharmacokinetics in patients with mild SARS-CoV-2 infection. mg/kg or placebo) and 2 (CT-P59 20 mg/kg or placebo) included a sentinel group of 2 subjects who were initially randomized 1:1 to receive CT-P59 or placebo. If no safety or tolerability concerns were reported within 48 hours of dosing the sentinel subjects, the remaining 6 subjects from the same cohort were randomized 5:1 to receive CT-P59 or placebo. In cohorts 3 (CT-P59 40 mg/kg or placebo) and 4 (CT-P59 80 mg/kg or placebo), 8 subjects were randomized in a 3:1 ratio to receive CT-P59 or placebo without a sentinel group. All subjects were followed for a total of 90 days post-infusion. Study 1.2 (EudraCT number: 2020-003165-19; NCT04593641) was conducted at 3 centers in the Republic of Korea and Romania. This study comprised 3 sequential dose cohorts (CT-P59 20, 40, or 80 mg/kg, or placebo), each including 6 patients who were randomized in a 5:1 ratio to receive CT-P59 or placebo via intravenous infusion. All patients will be followed for a total of 180 days postinfusion.

Dose escalation within and between studies is described in the supplementary material (p 2).

Healthy male or female subjects aged 19-55 years without SARS-CoV-2 infection were eligible for enrollment in study 1.1. All subjects were required to have body weight ≥50 kg and body mass index (BMI) of 18.0-29.9 kg/m 2 , and to be able to comply with all requirements of the protocol.

Adult male or female patients aged 18-60 years (or 18-70 years, if enrolled in the Republic of Korea) with mild symptoms of SARS-CoV-2 infection, confirmed by reverse transcription-polymerase chain reaction (RT-PCR), were eligible for enrollment in study 1.2. Patients were required to exhibit mild symptoms of SARS-CoV-2 infection, defined as oxygen saturation ≥94% on room air. Evidence of prespecified symptoms was required ≤7 days before study drug administration. Comprehensive eligibility criteria are provided in the supplementary material (p 2-7).

In study 1.1, a randomization code was generated by an unblinded statistician prior to the study, and was provided to an unblinded pharmacist in the study center. The pharmacist dispensed study drug based on the provided randomization lists. In study 1.2, randomization was performed using an interactive web response system by biostatisticians who were unblinded to treatment allocation. The study drug was dispensed by unblinded study center personnel who were not permitted to conduct any participant assessments. CT-P59 and placebo were prepared in identical 20-mL single-use vials containing identical excipients. The only difference between the CT-P59 and placebo formulations was the exclusion of the SARS-CoV-2 neutralizing monoclonal antibody from the placebo formulation. All other study center personnel, all participants, and investigators remained blinded to treatment allocation.

Both studies were conducted in compliance with the International Council for Harmonisation Good Clinical Practice and applicable regulatory requirements in accordance with the Declaration of Helsinki. The protocols and all applicable amendments were reviewed and approved by all relevant local independent ethics committees at each participating institution and national approval was granted, where required, prior to commencing the study. All participants provided written informed consent prior to any study-related procedures.

In study 1.1, subjects were admitted to the study center on day −1 prior to administration of study drug on day 1. Subjects were then discharged on day 4 after completion of a post-treatment 72-hour assessment. Confinement at the study site could be extended up to day 14 following drug administration according to the availability of the subjects and study center, and at the discretion of the investigator. In study 1.2, eligible patients were admitted to the study site and underwent screening. If participants still satisfied the eligibility criteria prior to dosing, they received the study drug on day 1 of the study. Confinement at the study site was required for a minimum of 72 hours.

In both studies, CT-P59 and placebo were administered via a 250-mL infusion solution of 0.9% weight/volume sodium chloride over 90 minutes. Monitoring for hypersensitivity reactions was conducted before dosing, at 15, 30, and 60 minutes from the start of the infusion, at completion of the infusion, and at 2, 3, 6, 12, and 24 hours after the start of infusion. Blood samples for pharmacokinetic assessment were taken before administration of the study drug, at the end of the infusion, at 1 hour after completion of the infusion on day 1 (also at 4, 8, and 12 hours post-infusion in study 1.1 only), and on days 2, 3, 5, 7, 10, 14, 28, 56, and 90. In study 1.2, nasopharyngeal swabs for assessment of viral shedding were taken before study drug administration, daily on days 2-7, and on days 10, 14, 21, and 28.

Patients in study 1.2 completed a SARS-CoV-2 Infection Symptom Checklist twice daily at approximately 12-hour intervals in the morning and evening until clinical recovery or day 28, whichever came first. The symptom checklist provides a patient rating of the intensity of 7 symptoms (feeling feverish, cough, shortness of breath or difficulty breathing, sore throat, body pain or muscle pain, fatigue, and headache) using a 4-point scoring scale of absent (0), mild (1), moderate (2) , and severe (3).

The final report describes study outcomes up to completion of the 90-day follow-up period in study 1.1 and the interim report describes study outcomes up to day 14 of follow-up in study 1.2. Secondary endpoints in both studies included pharmacokinetic analyses of CT-P59, additional safety monitoring, and the incidence of anti-drug antibodies (ADAs) and neutralizing antibodies over the entire study period. This report presents pharmacokinetic analyses conducted up to follow-up day 90 in study 1.1 and follow-up day 14 in study 1.2. Pharmacokinetic endpoints include maximum CT-P59 serum concentration (C max ), time to C max (T max ), and dose-normalized C max (C max /dose).

Additional pharmacokinetic endpoints assessed in study 1.1 were area under the serum concentration-time curve from time zero to infinity (AUC 0-inf ), dose-normalized AUC 0-inf (AUC 0inf /dose), terminal elimination half-life (t ½ ), total body clearance (CL), and volume of distribution during the terminal phase (Vz). Secondary endpoints in study 1.2 included virology, assessed using quantitative RT-PCR (RT-qPCR) and next-generation sequencing, to evaluate SARS-CoV-2 genetic variants at baseline and after treatment (Viroclinics Biosciences BV, Rotterdam, The Netherlands).

Infection Symptom Checklist recorded as "absent or mild" for at least 24 hours) and the number and proportion of patients with clinical recovery up to day 14.

Sample sizes in both studies were set empirically based on first-in-human clinical trial guidelines from the US Food and Drug Administration. 11 Planned enrollment was for 32 subjects in study 1.1 and 18 patients in study 1.2.

Safety analyses are based on the safety set that included all participants who had received a full or partial dose of CT-P59 or placebo. Pharmacokinetic analyses are based on the pharmacokinetic set, which includes all participants who had received a full dose of CT-P59 and had ≥1 evaluable post-treatment pharmacokinetic concentration result. Virologic and clinical efficacy analyses are based on the intent-to-treat set, defined as all participants randomly assigned to receive study drug, regardless of whether dosing was completed.

Continuous variables are reported using descriptive statistics, including the number of observations, means, standard deviations, medians, and interquartile ranges (IQRs), unless otherwise specified. Categorical variables are summarized using frequency tables showing the number and percentage of participants within each category.

Study 1.1 was initiated on 21 July 2020, with the last subject visit on 5 November 2020, wherein a total of 53 subjects were screened and 32 were randomized ( Figure 1A ). All randomized subjects were male and Asian, with a median age across cohorts of 24.0 years (IQR 22-30 years) (Table 1 ). There was no notable difference between dose cohorts in terms of age or BMI. In all 32 subjects, the actual dose administered was equivalent to the prescribed dose.

Predefined stopping criteria were not met; dosing of study drug in each cohort was completed per protocol. By day 14 post-infusion, AEs were reported in 2 subjects receiving CT-P59 20 mg/kg: 1 receiving CT-P59 40 mg/kg and 1 receiving placebo (all mild severity; CTCAE grade 1). There were no AEs reported in the CT-P59 10 mg/kg or 80 mg/kg cohorts. One subject receiving CT-P59 20 mg/kg developed a headache on day 3 after infusion, which was considered as probably related to the study drug and resolved on the same day with oral paracetamol. Another subject receiving CT-P59 20 mg/kg had increased C-reactive protein (CRP) levels on day 13 after infusion. CRP levels increased from 0.3 mg/dL on the day before study drug administration to 3.0 mg/dL on day 14 post-infusion.

This event was considered as possibly related to the study drug and resolved 2 weeks later without further intervention. One subject who received CT-P59 40 mg/kg developed pyrexia 1 day following study drug administration, with a body temperature increase from 37.6 °C to 38.2 °C. The investigator considered the event as probably related to the study drug; the fever resolved 1 day later without further intervention. One subject receiving placebo developed an IRR that initially manifested as dyspnea developing 15 minutes after the start of infusion but resolved with ongoing infusion. Two hours after starting study drug administration, the subject had a mild fever (38 °C) that resolved the following day without further intervention. There were no IRRs and no evidence of a hypersensitivity reaction in any subject receiving CT-P59.

No SAEs were reported when all subjects had completed 14 days of follow-up. There were no clinically meaningful changes in vital signs, electrocardiogram, or physical examination, and only 1 subject had a clinically meaningful change in laboratory values (increased CRP, as previously described). ADAs and neutralizing antibodies were not detected in any subject receiving CT-P59 up to day 7 of follow-up.

Between follow-up day 14 and follow-up day 90, an additional 5 AEs and 1 SAE were reported (Table 2 ; supplementary material p 7). The SAE was the result of an accident, and was considered unrelated to CT-P59. ADAs were not detected in any subject up to follow-up day 90.

CT-P59 C max , T max , C max /dose, AUC 0-inf , AUC 0-inf /dose, t ½ , CL, and Vz are presented in the supplementary material (p 5). The increase in the CT-P59 C max was proportional to dose over the dose range of 10-80 mg/kg, reaching T max at approximately 2 hours post-administration in all dose cohorts ( Figure 2 and Table S1 ). The 90% confidence interval (CI) for the slope between CT-P59 dose, C max and AUC 0-inf (log-transformed) included 1, with an 8.3-fold increase of C max and 6.6-fold increase in geometric mean AUC 0-inf (Table S2 ). Mean CT-P59 t ½ was between 16.6 days and 22.0 days and appeared to be unrelated to dose.

Study 1.2 was initiated on 4 September 2020. A total of 20 patients with mild SARS-CoV-2 infection were screened and 18 were randomized ( Figure 1B) . Patients in the 20 mg/kg dose cohort were enrolled at 2 study sites in the Republic of Korea; those in the 40 mg/kg and 80 mg/kg dose cohorts were enrolled at 1 study site in Romania. All patients in the CT-P59 20 mg/kg dose cohort were Asian; all those in the CT-P59 40 mg/kg and 80 mg/kg cohorts were White (Table 3) . Median age across all cohorts was 52.0 years (IQR 49-57 years). Among the risk factors for developing severe illness, no patients were aged >65 years and 5 patients had hypertension, obesity, or diabetes mellitus. All the higher-risk patients were included in the CT-P59 treatment groups. All 18 patients received a dose of study drug equivalent to the prescribed dose. Median time from symptom onset to administration of study drug was 4-6 days across the CT-P59 treatment groups and 4 days in the placebo group.

Predefined stopping criteria were not met; dosing of study drug in each cohort was completed per protocol. A total of 16 AEs were reported in 10 patients receiving CT-P59 and 3 AEs were reported in 1 patient receiving placebo ( Table 4 ). AEs of diarrhea and increased alanine aminotransferase (ALT) levels were each reported by 2 patients receiving CT-P59; all other AEs were reported by a single patient. All AEs were considered unrelated to the study drug. Grade 3 AEs were reported by 2 patients receiving CT-P59 40 mg/kg (hepatocellular injury and increased ALT concentration) and 1 patient receiving placebo (COVID-19 pneumonia). One patient with a medical history of obesity and hypertriglyceridemia who received CT-P59 40 mg/kg experienced grade 4 hypertriglyceridemia that was considered a worsening of the patient's preexisting condition. There were no SAEs, AEs leading to study discontinuation, or AEs of special interest (IRRs). There were no clinically meaningful changes in vital signs, hypersensitivity monitoring, electrocardiogram, radiography, physical examination, or SARS-CoV-2 infection-related signs and symptoms. There was also no evidence leading to suspicion of ADE or ADA-positive results at post-treatment visit up to day 14.

All patients had positive results for viral shedding based on RT-qPCR at baseline. Because of the variability in viral shedding at baseline, mean viral titers based on RT-qPCR were analyzed according to maximum viral titers. Overall, viral shedding in both the CT-P59 treatment groups and placebo group decreased over time. In patients with low maximum viral titers (<10 5 copies/mL), titers decreased regardless of study drug administration ( Figure 3A ). In patients with maximum viral titers of >10 5 copies/mL, decline in viral load was more rapid among patients receiving CT-P59 (20, 40, or 80 mg/kg) than those receiving placebo ( Figure 3B-D) . Of the 3 patients who received placebo, 2 had maximum viral titers of <10 5 copies/mL and 1 had maximum titer of >10 5 copies/mL. Overall, mean change from baseline for viral titers in nasopharyngeal swab specimens based on RT-qPCR was generally greater in the CT-P59 treatment groups than placebo up to day 14 (Table S3 ).

None of the enrolled patients had an allele frequency of ≥15% for Q493K or S494P variants.

Such substitutions in the S protein RBD have been identified in non-clinical neutralization assays as reducing susceptibility to CT-P59. Variants with N501Y, E484K, and K417N mutations, associated with the alpha ("United Kingdom") and beta ("South African") variants, were also not observed at an allele frequency of ≥15% at baseline or after study drug administration.

Except for 1 placebo recipient, all patients recovered by day 14 (Table S4) 

Overall, pharmacokinetic results confirmed that exposure to CT-P59 increased with dose over the studied range of 20-80 mg/kg (Figure 4 ; Table S5 ). CT-P59 C max increased in a greater than doseproportional manner. The 90% CI for the slope between CT-P59 dose and C max (both logtransformed) was 1.21 with 90% CIs that excluded 1 (1.074-1.355) (Table S2 ). In all cohorts, median T max was reached 2.5 hours post-administration (Table S5) infection. 5, 7 Convalescent plasma therapy, in which blood plasma from a recovered patient is transfused to a symptomatic patient, is also undergoing evaluation. [12] [13] [14] Finally, the RBD-specific antibodies, REGN-COV-2 and LY-CoV555, are both being studied for the treatment of SARS-CoV-2 infection. [15] [16] [17] REGN-COV-2 is a cocktail of 2 antibodies targeting non-overlapping epitopes on the S protein, developed to mitigate the risk of escape mutations emerging under therapeutic pressure. 15, 17 LY-CoV555 is also an RBD-specific antibody that has been shown to protect the upper and lower airways from SARS-CoV-2 infection in a primate model of infection. 16 Early clinical data indicate a reduction in viral load with LY-CoV555 (2800 mg) relative to placebo in patients with mild or moderate SARS-CoV-2 infection; however, these findings were not replicated in patients receiving the higher 7000 mg dose. 18 There are limitations to drawing statistically robust conclusions about the differences between the groups in these phase 1 studies, given the small sample size. However, the safety, virology, efficacy, and pharmacokinetics of CT-P59 will be further evaluated in a large number of patients in 2 phase 3 studies of CT-P59, which will offer greater statistical power to determine differences between CT-P59 and placebo. As studies 1.1 and 1.2 were the first to evaluate CT-P59 in healthy volunteers and patients with mild SARS-CoV-2 infection, patients with comorbidities considered clinically significant by the investigator were not enrolled. Furthermore, evaluation of efficacy in study 1.2 was limited by the inclusion of only 3 patients in the placebo group, 2 of whom had low maximum viral titers (<10 5 copies/mL). Efficacy comparisons between CT-P59 and placebo in patients with high maximum viral titers (>10 5 copies /mL) therefore include only 1 patient in the placebo group. Moreover, since this was an interim analysis of study 1.2, additional data from patients with SARS-CoV-2 infection who complete 180 days of follow-up, including further clinical outcomes, will form the basis of a later report.

Since initiating this study, a number of key variants of SARS-CoV-2 have been identified and become prevalent. Because study 1.2 was initiated on 4 September 2020, patients enrolled in this study are unlikely to have been exposed to the emerging variants in the countries where the study 

The study protocol / clinical study plan are provided in the supplementary material (p 2). Data are not publicly shared as they contain participants' personal and confidential information. However, appropriate data can be made available upon request after confirmation by the Sponsor. Male sex, n (%) 6 (100) 6 (100) 6 (100) 6 (100) 8 (100) 32 (100) Asian race, n (%) 6 (100) 6 (100) 6 (100) 6 (100) 8 There were no SAEs, AEs leading to study discontinuation, AEs of special interest (infusion-related reaction including hypersensitivity and anaphylactic reaction), or deaths. c All AEs were considered by the investigator to be unrelated to study drug.

World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard

Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Potently neutralizing and protective human antibodies against SARS-CoV-2

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein

Expansion cohorts: use in first-in-human clinical trials to expedite development of oncology drugs and biologics guidance for industry

Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma

Hospitalized COVID-19 patients treated with convalescent plasma in a mid-size city in the Midwest

Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19

Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant

The authors thank all participants and investigators involved in the studies. Medical writing support 

None.